NCT04495790: AIMS Cancer Outcomes Study

NCT04495790
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: 
Additional Notes: Patients must be established at the Advanced Integrative Medical Science Institute
Exclusions: 
https://ClinicalTrials.gov/show/NCT04495790

Comments are closed.

Up ↑